NUWELLIS INC (NUWE) Fundamental Analysis & Valuation

NASDAQ:NUWE • US67113Y7022

Current stock price

1.04 USD
-0.04 (-3.7%)
Last:

This NUWE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NUWE Profitability Analysis

1.1 Basic Checks

  • NUWE had negative earnings in the past year.
  • NUWE had a negative operating cash flow in the past year.
  • NUWE had negative earnings in each of the past 5 years.
  • NUWE had a negative operating cash flow in each of the past 5 years.
NUWE Yearly Net Income VS EBIT VS OCF VS FCFNUWE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of NUWE (-207.46%) is worse than 91.30% of its industry peers.
  • NUWE has a Return On Equity of -423.19%. This is amonst the worse of the industry: NUWE underperforms 82.07% of its industry peers.
Industry RankSector Rank
ROA -207.46%
ROE -423.19%
ROIC N/A
ROA(3y)-132.73%
ROA(5y)-110.12%
ROE(3y)-328.31%
ROE(5y)-233.66%
ROIC(3y)N/A
ROIC(5y)N/A
NUWE Yearly ROA, ROE, ROICNUWE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • With a Gross Margin value of 59.07%, NUWE perfoms like the industry average, outperforming 59.24% of the companies in the same industry.
  • NUWE's Gross Margin has improved in the last couple of years.
  • NUWE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.63%
GM growth 5Y4.66%
NUWE Yearly Profit, Operating, Gross MarginsNUWE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NUWE Health Analysis

2.1 Basic Checks

  • NUWE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NUWE has more shares outstanding
  • Compared to 5 years ago, NUWE has more shares outstanding
  • NUWE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUWE Yearly Shares OutstandingNUWE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
NUWE Yearly Total Debt VS Total AssetsNUWE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • NUWE has an Altman-Z score of -57.66. This is a bad value and indicates that NUWE is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NUWE (-57.66) is worse than 94.57% of its industry peers.
  • There is no outstanding debt for NUWE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -57.66
ROIC/WACCN/A
WACC10.13%
NUWE Yearly LT Debt VS Equity VS FCFNUWE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 2.04 indicates that NUWE has no problem at all paying its short term obligations.
  • NUWE's Current ratio of 2.04 is on the low side compared to the rest of the industry. NUWE is outperformed by 62.50% of its industry peers.
  • NUWE has a Quick Ratio of 1.42. This is a normal value and indicates that NUWE is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of NUWE (1.42) is worse than 61.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 1.42
NUWE Yearly Current Assets VS Current LiabilitesNUWE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NUWE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 91.32% over the past year.
  • Looking at the last year, NUWE shows a decrease in Revenue. The Revenue has decreased by -1.40% in the last year.
  • Measured over the past years, NUWE shows a quite strong growth in Revenue. The Revenue has been growing by 9.67% on average per year.
EPS 1Y (TTM)91.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.9%
Revenue 1Y (TTM)-1.4%
Revenue growth 3Y3.34%
Revenue growth 5Y9.67%
Sales Q2Q%4.39%

3.2 Future

  • NUWE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.98% yearly.
  • Based on estimates for the next years, NUWE will show a very strong growth in Revenue. The Revenue will grow by 45.06% on average per year.
EPS Next Y98.39%
EPS Next 2Y41.38%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue Next Year-8.15%
Revenue Next 2Y0.74%
Revenue Next 3Y6.34%
Revenue Next 5Y45.06%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NUWE Yearly Revenue VS EstimatesNUWE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
NUWE Yearly EPS VS EstimatesNUWE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10B -20B -30B -40B -50B

More info and screens

Find the best growth stocksShow best growing peers

1

4. NUWE Valuation Analysis

4.1 Price/Earnings Ratio

  • NUWE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUWE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUWE Price Earnings VS Forward Price EarningsNUWE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUWE Per share dataNUWE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K

4.3 Compensation for Growth

  • NUWE's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.38%
EPS Next 3Y25.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NUWE Dividend Analysis

5.1 Amount

  • No dividends for NUWE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUWE Fundamentals: All Metrics, Ratios and Statistics

NUWELLIS INC

NASDAQ:NUWE (3/18/2026, 4:32:27 PM)

1.04

-0.04 (-3.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-10
Earnings (Next)05-11
Inst Owners7.34%
Inst Owner Change69.36%
Ins Owners0.02%
Ins Owner Change0%
Market Cap2.40M
Revenue(TTM)8.74M
Net Income(TTM)-16.56M
Analysts43.33
Price TargetN/A
Short Float %1.5%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-18.09%
Min Revenue beat(2)-23.13%
Max Revenue beat(2)-13.06%
Revenue beat(4)0
Avg Revenue beat(4)-15.38%
Min Revenue beat(4)-23.13%
Max Revenue beat(4)-7.53%
Revenue beat(8)1
Avg Revenue beat(8)-8.34%
Revenue beat(12)3
Avg Revenue beat(12)-7.48%
Revenue beat(16)5
Avg Revenue beat(16)-7.29%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-1630.02
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-4.07
FCFYN/A
OCF(TTM)-4.02
OCFYN/A
SpS3.54
BVpS1.69
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -207.46%
ROE -423.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.07%
FCFM N/A
ROA(3y)-132.73%
ROA(5y)-110.12%
ROE(3y)-328.31%
ROE(5y)-233.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.63%
GM growth 5Y4.66%
F-Score4
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.2%
Cap/Sales 1.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.04
Quick Ratio 1.42
Altman-Z -57.66
F-Score4
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)40.1%
Cap/Depr(5y)48.83%
Cap/Sales(3y)1.63%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.9%
EPS Next Y98.39%
EPS Next 2Y41.38%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.4%
Revenue growth 3Y3.34%
Revenue growth 5Y9.67%
Sales Q2Q%4.39%
Revenue Next Year-8.15%
Revenue Next 2Y0.74%
Revenue Next 3Y6.34%
Revenue Next 5Y45.06%
EBIT growth 1Y9.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.3%
OCF growth 3YN/A
OCF growth 5YN/A

NUWELLIS INC / NUWE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NUWELLIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to NUWE.


Can you provide the valuation status for NUWELLIS INC?

ChartMill assigns a valuation rating of 1 / 10 to NUWELLIS INC (NUWE). This can be considered as Overvalued.


What is the profitability of NUWE stock?

NUWELLIS INC (NUWE) has a profitability rating of 1 / 10.


What is the financial health of NUWELLIS INC (NUWE) stock?

The financial health rating of NUWELLIS INC (NUWE) is 5 / 10.